Paradigm Biocapital Advisors LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Paradigm Biocapital Advisors LP reported 35 stock positions worth $2.6 billion. Its top holding was Nuvalent Class A (NUVL) at 13.3% of the portfolio, followed by Argenx SE - ADR (ARGX, 8.9%) and Arcellx (ACLX, 8.1%). Compared with Q1 2024, it opened 10 new positions, sold out of 9, added to 10 and reduced 11. The biggest buy was a new position in Merus (MRUS) and the biggest sale an exit from Immunocore Holdings PLC-ADR (IMCR).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001855655
- Portfolio Value
- $2.6B (Q2 2024)
- SEC Filing
- 0001855655-24-000009 ↗ filed Aug 14, 2024
Holdings Value
Holdings 35 stocks · $2.6B
| NUVL Nuvalent Inc. Class A | 13.27% | 4,571,678 | $346.8M | Add +9.4% |
| ARGX Argenx SE - ADR | 8.86% | 538,139 | $231.4M | Reduce -2.5% |
| ACLX Arcellx Inc. | 8.13% | 3,848,095 | $212.4M | Add +0.8% |
| RVMD Revolution Medicines Inc. | 7.81% | 5,259,089 | $204.1M | Add +80.4% |
| SRPT Sarepta Therapeutics Inc. | 5.73% | 947,574 | $149.7M | Reduce -12.1% |
| IRON Disc Medicine Inc. | 4.67% | 2,704,718 | $121.9M | Add +13.2% |
| MRUS Merus NV | 4.57% | 2,019,814 | $119.5M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 4.31% | 2,513,302 | $112.6M | Reduce -19.6% |
| CERE Cerevel Therapeutics Holding | 3.65% | 2,330,508 | $95.3M | No change |
| KURA Kura Oncology Inc. | 3.58% | 4,539,381 | $93.5M | Add +44.8% |
| ASND Ascendis Pharma A/S | 3.47% | 664,307 | $90.6M | Add +30.8% |
| OLMA Olema Pharmaceuticals Inc. | 3.27% | 7,903,600 | $85.5M | No change |
| XENE Xenon Pharmaceuticals Inc. | 3.05% | 2,043,280 | $79.7M | Reduce -17.8% |
| TARS Tarsus Pharmaceuticals Inc. | 2.53% | 2,435,416 | $66.2M | Reduce -14.9% |
| JANX Janux Therapeutics Inc. | 2.51% | 1,564,452 | $65.5M | New |
| ARVN Arvinas Inc. | 2.48% | 2,438,149 | $64.9M | Reduce -6.8% |
| LEGN Legend Biotech Corp.-ADR | 2.04% | 1,203,308 | $53.3M | Reduce -39.3% |
| PCVX Vaxcyte Inc. | 1.81% | 627,202 | $47.4M | Reduce -49.4% |
| YMAB Y-Mabs Therapeutics Inc. | 1.79% | 3,870,594 | $46.8M | Add +73.3% |
| EWTX Edgewise Therapeutics Inc. | 1.60% | 2,325,449 | $41.9M | Reduce -4.9% |
| IMTX Immatics NV | 1.52% | 3,421,965 | $39.8M | Add +21.4% |
| VRDN Viridian Therapeutics Inc. | 1.44% | 2,896,349 | $37.7M | Reduce -42.4% |
| IMVT Immunovant Inc. | 1.38% | 1,362,827 | $36.0M | Add +70.6% |
| COGT Cogent Biosciences Inc. | 1.17% | 3,624,342 | $30.6M | New |
| BBIO Bridgebio Pharma Inc. | 1.06% | 1,089,492 | $27.6M | New |
| CGEM Cullinan Therapeutics Inc. | 1.03% | 1,542,805 | $26.9M | Add +14.4% |
| ERAS Erasca Inc. | 0.65% | 7,250,000 | $17.1M | New |
| CMPS Compass Pathways PLC | 0.54% | 2,335,926 | $14.1M | Reduce -2.3% |
| APGE Apogee Therapeutics Inc. | 0.50% | 330,000 | $13.0M | No change |
| VRNA Verona Pharma Ltd. | 0.40% | 721,087 | $10.4M | New |
| ALXO Alx Oncology Holdings Inc. | 0.36% | 1,575,605 | $9.5M | New |
| CATX Perspective Therapeutics Inc. | 0.35% | 919,692 | $9.2M | New |
| VOR Vor Biopharma Inc. | 0.25% | 6,457,293 | $6.5M | No change |
| ACRV Acrivon Therapeutics Inc. | 0.15% | 659,724 | $3.8M | New |
| TCRX Tscan Therapeutics Inc. | 0.08% | 353,886 | $2.1M | New |
Portfolio Sells Q1 2024 → Q2 2024
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −4.09 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −2.96 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −2.85 |
| LEGN Legend Biotech Corp.-ADR | Reduce -39.3% | 2.04% | −1.87 |
| VRDN Viridian Therapeutics Inc. | Reduce -42.4% | 1.44% | −1.66 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −1.44 |
| ARVN Arvinas Inc. | Reduce -6.8% | 2.48% | −1.32 |
| PCVX Vaxcyte Inc. | Reduce -49.4% | 1.81% | −1.17 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -14.9% | 2.53% | −1.13 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -19.6% | 4.31% | −0.84 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -17.8% | 3.05% | −0.72 |
| ZNTL Zentalis Pharmaceuticals Inc. | Sold out | 0.00% | −0.52 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.41 |
| CRBU Caribou Biosciences Inc. | Sold out | 0.00% | −0.39 |
| CMPS Compass Pathways PLC | Reduce -2.3% | 0.54% | −0.16 |
| CRGX Cargo Therapeutics Inc. | Sold out | 0.00% | −0.12 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| EWTX Edgewise Therapeutics Inc. | Reduce -4.9% | 1.60% | +0.03 |
| SRPT Sarepta Therapeutics Inc. | Reduce -12.1% | 5.73% | +0.82 |
| ARGX Argenx SE - ADR | Reduce -2.5% | 8.86% | +1.20 |
Portfolio Buys Q1 2024 → Q2 2024
| MRUS Merus NV | New | 4.57% | +4.57 |
| RVMD Revolution Medicines Inc. | Add +80.4% | 7.81% | +4.50 |
| JANX Janux Therapeutics Inc. | New | 2.51% | +2.51 |
| NUVL Nuvalent Inc. Class A | Add +9.4% | 13.27% | +2.23 |
| KURA Kura Oncology Inc. | Add +44.8% | 3.58% | +1.22 |
| COGT Cogent Biosciences Inc. | New | 1.17% | +1.17 |
| BBIO Bridgebio Pharma Inc. | New | 1.06% | +1.06 |
| ASND Ascendis Pharma A/S | Add +30.8% | 3.47% | +0.76 |
| ERAS Erasca Inc. | New | 0.65% | +0.65 |
| YMAB Y-Mabs Therapeutics Inc. | Add +73.3% | 1.79% | +0.51 |
| IMTX Immatics NV | Add +21.4% | 1.52% | +0.48 |
| IMVT Immunovant Inc. | Add +70.6% | 1.38% | +0.47 |
| VRNA Verona Pharma Ltd. | New | 0.40% | +0.40 |
| ALXO Alx Oncology Holdings Inc. | New | 0.36% | +0.36 |
| CATX Perspective Therapeutics Inc. | New | 0.35% | +0.35 |
| CGEM Cullinan Therapeutics Inc. | Add +14.4% | 1.03% | +0.22 |
| ACRV Acrivon Therapeutics Inc. | New | 0.15% | +0.15 |
| TCRX Tscan Therapeutics Inc. | New | 0.08% | +0.08 |
| IRON Disc Medicine Inc. | Add +13.2% | 4.67% | −0.57 |
| ACLX Arcellx Inc. | Add +0.8% | 8.13% | −1.22 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 28 | $5.3B | RVMD, NUVL, EWTX, GMAB, SYRE |
| Q1 2026 | 35 | $4.9B | ACLX, RVMD, NUVL, PCVX, EWTX |
| Q4 2025 | 29 | $3.7B | NUVL, RVMD, ACLX, GMAB, TARS |
| Q3 2025 | 33 | $3.4B | NUVL, MRUS, ACLX, RVMD, TARS |
| Q2 2025 | 28 | $2.3B | NUVL, ACLX, MRUS, RVMD, TARS |
| Q1 2025 | 27 | $2.2B | NUVL, ACLX, RVMD, ONC, MRUS |
| Q4 2024 | 28 | $2.9B | NUVL, ACLX, ARGX, RVMD, JANX |
| Q3 2024 | 31 | $2.9B | NUVL, ACLX, ARGX, RVMD, CRNX |
| Q2 2024 | 35 | $2.6B | NUVL, ARGX, ACLX, RVMD, SRPT |
| Q1 2024 | 34 | $2.8B | NUVL, ACLX, ARGX, IRON, CRNX |